Effects of Dutasteride on Prostate Growth in the Large Probasin-Large T Antigen Mouse Model of Prostate Cancer

Journal of Urology

Volumn 178, Issue 4, 2007, Pages 1521-1527

  Shao, T C ^a,b   Li, H ^a,b   Ittmann, M ^a,b   Cunningham, G R ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

dutasteride; mice; prostate; prostatic hyperplasia; prostatic neoplasms; transgenic

Indexed keywords

5ALPHA REDUCTASE 1; 5ALPHA REDUCTASE 2; ANDROGEN; DNA; DUTASTERIDE; PROBASIN; PROSTATE ANTIGEN; PROSTATE PROTEIN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BULBOCAVERNOSUS MUSCLE; CANCER GROWTH; CANCER INHIBITION; CASTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; LEVATOR ANI MUSCLE; MALE; MOUSE; MUSCLE; MUSCLE MASS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; SEMINAL VESICLE; STROMA CELL; TRANSGENE; TRANSGENIC MOUSE; TUMOR DIFFERENTIATION;

ANDROGEN-BINDING PROTEIN; ANIMALS; ANTIGENS, VIRAL, TUMOR; APOPTOSIS; AZASTEROIDS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DIHYDROTESTOSTERONE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SEMINAL VESICLES; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSGENES;

EID: 34548398124     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.118     Document Type: Article

References (19)

1. Bott S.R., Birtle A.J., Taylor C.J., and Kirby R.S. Prostate cancer management: 2. An update on locally advanced and metastatic disease. Postgrad Med J 79 (2003) 643
2. Gormley G.J., Stoner E., Bruskewitz R.C., Imperato-McGinley J., Walsh P.C., McConnell J.D., et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327 (1992) 1185
3. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
4. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434
5. Stuart J.D., Lee F.W., SimpsonNoel D., Kadwell S.H., Overton L.K., Hoffman C.R., et al. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat. Biochem Pharmacol 62 (2001) 933
6. Kasper S., Sheppard P.C., Yan Y., Pettigrew N., Borowsky A.D., Prins G.S., et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 781 (1998) i
7. Shao T.C., Li H.L., Kasper S., Matusik R., Ittmann M., and Cunningham G.R. Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. Prostate 66 (2006) 369
8. Shao T.C., Kong A., and Cunningham G.R. Effects of 4-MAPC, a 5 alpha-reductase inhibitor, and cyproterone acetate on regrowth of the rat ventral prostate. Prostate 24 (1994) 212
9. Prahalada S., Rhodes L., Grossman S.J., Heggan D., Keenan K.P., Cukierski M.A., et al. Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor. Prostate 35 (1998) 157
10. Rittmaster R.S., Manning A.P., Wright A.S., Thomas L.N., Whitefield S., Norman R.W., et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology 136 (1995) 741
11. Maria McCrohan A., Morrissey C., O'Keane C., Mulligan N., Watson C., Smith J., et al. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer 106 (2006) 2743
12. Xu Y., Dalrymple S.L., Becker R.E., Denmeade S.R., and Isaacs J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12 (2006) 4072
13. Esmat A.Y., Refaie F.M., Shaheen M.H., and Said M.M. Chemoprevention of prostate carcinogenesis by DFMO and/or finasteride treatment in male Wistar rats. Tumori 88 (2002) 513
14. Bonkhoff H., Stein U., Aumuller G., and Remberger K. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29 (1996) 261
15. Bruchovsky N., Sadar M.D., Akakura K., Goldenberg S.L., Matsuoka K., and Rennie P.S. Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 59 (1996) 397
16. Thomas L.N., Douglas R.C., Vessey J.P., Gupta R., Fontaine D., Norman R.W., et al. 5α-Reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 170 (2003) 2019
17. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
18. Andriole G.L., Roehrborn C., Schulman C., Slawin K.M., Somerville M., and Rittmaster R.S. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 (2004) 537
19. Andriole G., Bostwick D., Brawley O., Gomella L., Marberger M., Tindall D., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 (2004) 1314